IMGN - ImmunoGen, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.4100
-0.1600 (-6.23%)
At close: 4:00PM EDT

2.4100 0.00 (0.00%)
After hours: 4:48PM EDT

Stock chart is not supported by your current browser
Previous Close2.5700
Open2.5600
Bid2.4200 x 27000
Ask2.4200 x 36100
Day's Range2.4000 - 2.6200
52 Week Range2.2700 - 13.4100
Volume2,607,127
Avg. Volume3,775,160
Market Cap360.078M
Beta (3Y Monthly)2.44
PE Ratio (TTM)N/A
EPS (TTM)-1.2060
Earnings DateMay 2, 2019 - May 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.38
Trade prices are not sourced from all markets
  • Options Traders Expect Huge Moves in ImmunoGen (IMGN) Stock
    Zacks10 days ago

    Options Traders Expect Huge Moves in ImmunoGen (IMGN) Stock

    Investors need to pay close attention to ImmunoGen (IMGN) stock based on the movements in the options market lately.

  • ImmunoGen (IMGN) Down 50.2% Since Last Earnings Report: Can It Rebound?
    Zacks12 days ago

    ImmunoGen (IMGN) Down 50.2% Since Last Earnings Report: Can It Rebound?

    ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GuruFocus.com16 days ago

    ImmunoGen Failure Casts a Shadow on Antibody-Drug Conjugates

    Flagship ImmunoGen (IMGN) ovarian cancer drug candidate Mirvetuximab Soravtansine just failed to meet its primary endpoint in Phase III studies. The failed candidate is an antibody-drug conjugate (ADC), a drug model that uses an antibody as a homing device to lock on to cancer cells and deliver a targeted drug payload. The entire ADC approach to cancer treatment could arguably be called into question here.

  • ACCESSWIRE16 days ago

    Four Biotech Stocks Setting The Standard on Wednesday

    CORAL GABLES, FL / ACCESSWIRE / March 6, 2019 / The ascendancy of the biotech stock market to where it is today has only been made possible by the fact that biotech companies continue to formulate and manufacture top-of-the-line technologies for the purpose of the betterment of the human experience. Premier Health Group (OTC:PHGRF) (CSE:PHGI), ImmunoGen Inc (IMGN), Tenax Therapeutics Inc (NASDAQ:TENX) and 22nd Century Group Inc (NYSE American: XXII) are four biotech companies focused on investing in the future of humanity. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company which is leading the healthcare industry in developing innovative approaches that combine human skill-based expertise with state-of-the-art technologies to create a patient-centric healthcare framework.

  • Biotech Stock Roundup: BIIB to Acquire Nightstar, Other Pipeline News & More
    Zacks16 days ago

    Biotech Stock Roundup: BIIB to Acquire Nightstar, Other Pipeline News & More

    Key highlights of the past week are merger agreements plus regulatory and pipeline developments.

  • Immunogen Ovarian Cancer Drug Fails in Phase III, Stock Sinks
    Zacks18 days ago

    Immunogen Ovarian Cancer Drug Fails in Phase III, Stock Sinks

    Immunogen's (IMGN) ovarian cancer candidate, mirvetuximab soravtansine fails to meet primary endpoint in a phase III monotherapy study. Shares of the company decline almost 47%.

  • Why ImmunoGen Tanked on Friday
    Market Realist18 days ago

    Why ImmunoGen Tanked on Friday

    Why ImmunoGen Tanked on FridayStock price movements On March 1, ImmunoGen (IMGN) closed at $2.51, 46.82% lower than its previous closing price. At the end of Friday, the company had a market capitalization of $369.52 million. The dramatic drop in

  • GuruFocus.com20 days ago

    Immunogen Inc (IMGN) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Immunogen Inc is a clinical-stage biotechnology company that develops targeted anticancer therapeutics. Warning! GuruFocus has detected 4 Warning Signs with IMGN. For the last quarter Immunogen Inc reported a revenue of $13.8 million, compared with the revenue of $39.45 million during the same period a year ago.

  • TheStreet.com21 days ago

    Immunogen Tanks After Ovarian Cancer Drug Study Fails to Meet Endpoint

    was down more than 45% in trading Friday after the company's ovarian cancer treatment candidate failed to meet the primary endpoint in a phase 3 trial. The trial evaluated the efficacy of its treatment candidate compared to the results of treatment with chemotherapy in patients with folate receptor alpha positive, platinum-resistant ovarian cancer. "Even though FORWARD I did not meet its primary endpoint, I continue to be impressed with the efficacy and tolerability of mirvetuximab soravtansine in ovarian cancer patients, especially in the subset with high FRα expression," said Dr. Kathleen Moore, associate director of clinical research at the Stephenson Cancer Center at the University of Oklahoma.

  • Why ImmunoGen Stock Is Crashing Today
    Motley Fool21 days ago

    Why ImmunoGen Stock Is Crashing Today

    The biotech reported a big clinical setback for its lead ovarian cancer candidate.

  • Shares of Waltham drugmaker ImmunoGen crater after late-stage trial fail
    American City Business Journals21 days ago

    Shares of Waltham drugmaker ImmunoGen crater after late-stage trial fail

    The drugmaker, which has more than 200 employees, reported Friday morning that its ovarian cancer drug failed to lead to a longer survival rate without the cancer spreading.

  • MarketWatch21 days ago

    Immunogen's stock loses nearly half its value after trial of cancer treatment fails to meet primary endpoint

    Shares of Immunogen Inc. plummeted 48% toward a two-year low in premarket trade Friday, after the company said a phase 3 trial of its ovarian cancer treatment, mirvetuximab soravtansine, compared to chemotherapy, failed to meet its primary endpoint of progression free survival. The company said that based on the efficacy signals, overall response rate and survival, it will conduct additional analysis to evaluation the potential benefit of mirvetuximab soravtansine for FRα-positive platinum-resistant ovarian cancer. "ImmunoGen is in a strong financial position with approximately $295 million in cash on our balance sheet, and we will continue to advance our portfolio of next-generation ADCs, which includes three additional development candidates targeting a range of tumor types in both hematologic malignancies and solid tumors," said Chief Executive Mark Enyedy. The stock has tumbled 57% over the past 12 months through Thursday, while the iShares Nasdaq Biotechnology ETF has gained 5.3% and the S&P 500 has tacked on 4.0%.

  • Reuters21 days ago

    ImmunoGen's ovarian cancer drug fails in late-stage study

    U.S. drug developer ImmunoGen Inc said on Friday its experimental ovarian cancer drug failed to meet the main goal of a late-stage study. When compared with chemotherapy, the drug, mirvetuximab soravtansine, ...

  • Business Wire21 days ago

    ImmunoGen Announces Top-Line Results from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer

    ImmunoGen, Inc., (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that its Phase 3 FORWARD I trial evaluating the safety and efficacy of mirvetuximab soravtansine compared to chemotherapy in patients with folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival (PFS) in either the entire study population or in the pre-specified subset of patients with high FRα expression.

  • Why ImmunoGen Tumbled 20.3% Today
    Motley Fool23 days ago

    Why ImmunoGen Tumbled 20.3% Today

    Shares sold off Wednesday in anticipation of market-moving news.

  • Business Wire23 days ago

    ImmunoGen Announces Multiple Presentations at AACR Annual Meeting

    WALTHAM, Mass.-- -- Continued Innovation in ADCs Highlighted in Eleven Posters First-in-Class ADAM9-targeting ADC, IMGC936, Developed in Collaboration with MacroGenics, Demonstrates Preclinical Activity in Models of Non-Small Cell Lung, Gastric, and Colorectal Cancers Novel DARPin ® Drug Conjugate Platform Evaluated in Collaboration with Molecular Partners AG ImmunoGen, Inc. , , a leader in the expanding ...

  • GlobeNewswire28 days ago

    Factors of Influence in 2019, Key Indicators and Opportunity within Apple, United Continental, ImmunoGen, CymaBay Therapeutics, Granite Construction, and Flotek Industries — New Research Emphasizes Economic Growth

    NEW YORK, Feb. 22, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE29 days ago

    Healthcare Companies Investors are Watching

    HENDERSON, NV / ACCESSWIRE / February 21, 2018 / The healthcare sector provides investors with some of the biggest profit opportunities in the whole market. An oversold stock in the sector we think you ...

  • How ImmunoGen, Inc. (NASDAQ:IMGN) Could Add Value To Your Portfolio
    Simply Wall St.last month

    How ImmunoGen, Inc. (NASDAQ:IMGN) Could Add Value To Your Portfolio

    Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! ImmunoGen, Inc. (NASDAQ:IMGN) is a company with exceptional fundamental characteristics.Read More...

  • Thomson Reuters StreetEventslast month

    Edited Transcript of IMGN earnings conference call or presentation 8-Feb-19 1:00pm GMT

    Q4 2018 ImmunoGen Inc Earnings Call

  • ImmunoGen Still Waiting to Take Its Leap "Forward"
    Motley Foollast month

    ImmunoGen Still Waiting to Take Its Leap "Forward"

    Data from a late-stage clinical trial is expected in the first half of this year.

  • ImmunoGen (IMGN) Beats on Earnings & Sales in Q4, Shares Up
    Zackslast month

    ImmunoGen (IMGN) Beats on Earnings & Sales in Q4, Shares Up

    ImmunoGen (IMGN) reports narrower-than-expected loss in Q4 and beats revenue estimates.

  • ImmunoGen (IMGN) Q4 2018 Earnings Conference Call Transcript
    Motley Foollast month

    ImmunoGen (IMGN) Q4 2018 Earnings Conference Call Transcript

    IMGN earnings call for the period ending December 31, 2018.

  • ImmunoGen (IMGN) Reports Q4 Loss, Tops Revenue Estimates
    Zackslast month

    ImmunoGen (IMGN) Reports Q4 Loss, Tops Revenue Estimates

    ImmunoGen (IMGN) delivered earnings and revenue surprises of 15.15% and 14.97%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?